Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Avalo Therapeutics, Inc. (AVTX : NSDQ)

• Company Description    Avalo Therapeutics Inc. is a clinical-stage precision medicine company which discovers, develops and commercializes targeted therapeutics for patients with significant unmet clinical need in immunology, immuno-oncology and rare genetic diseases. Avalo Therapeutics Inc., formerly known as Cerecor, is based in WAYNE, Pa. Number of Employees: 33

• Price / Volume Information    Yesterday's Closing Price: $16.35 Daily Weekly Monthly 20 Day Moving Average: 2,789,259 shares Shares Outstanding: 52.57 (millions) Market Capitalization: $859.45 (millions) Beta: 0.78 52 Week High: $24.27 52 Week Low: $3.43 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 10.85% 5.43% 12 Week -7.31% -14.32% Year To Date -9.97% -15.96%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1500 Liberty Ridge Drive Suite 321 - Wayne,PA 19087 USA ph: 410-522-8707 fax: - ir@avalotx.com http://www.avalotx.com

• General Corporate Information    Officers Garry Neil - Chief Executive Officer and Director Michael Heffernan - Chairman and Director Christopher Sullivan - Chief Financial Officer Mitchell Chan - Director Jonathan Goldman - Director Peer Information Avalo Therapeutics, Inc. (GSAC) Avalo Therapeutics, Inc. (CASIF) Avalo Therapeutics, Inc. (ALCD.) Avalo Therapeutics, Inc. (OMNN) Avalo Therapeutics, Inc. (CGPI.) Avalo Therapeutics, Inc. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 05338F306 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/06/26 Share - Related Items Shares Outstanding: 52.57 Most Recent Split Date: 12.00 (0.00:1) Beta: 0.78 Market Capitalization: $859.45 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.68 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.72 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/06/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 12.58 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 21.60% vs. Previous Quarter: -164.86% Sales Growth vs. Year Ago Period: -69.27% vs. Previous Quarter: -% ROE 03/31/26 - -97.54 12/31/25 - -77.91 09/30/25 - -88.43 ROA 03/31/26 - -72.42 12/31/25 - -61.78 09/30/25 - -73.86 Current Ratio 03/31/26 - 7.66 12/31/25 - 8.14 09/30/25 - 14.28 Quick Ratio 03/31/26 - 7.66 12/31/25 - 8.14 09/30/25 - 14.28 Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Pre-Tax Margin 03/31/26 - -143,340.69 12/31/25 - -132,362.72 09/30/25 - -51,942.19 Book Value 03/31/26 - 1.30 12/31/25 - 4.49 09/30/25 - 5.14 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00

Powered by Zacks Investment Research ©